Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab.

Dong-A ST Co., Ltd.1,971 enrolled

Overview

Multi-center, open, non-intervention and observational study to Evaluate the efficacy and safety of Suganon tab. or Sugamet XR tab. in patients with Type 2 diabetes

Study Type

OBSERVATIONAL

Enrollment

1,971

Conditions

Diabetes Mellitus, Type 2

Interventions

EvogliptinDRUG

Evogliptin

EvogliptinDRUG

Evogliptin

Metformin and EvogliptinDRUG

Metformin and Evogliptin

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. The subject is aged ≥19 years 2. The subject has type 2 diabetes mellitus Exclusion Criteria: 1\. The subject has a contraindication

Locations (1)

Sanggye paik pospital

Seoul, Nowon-gu, South Korea

RECRUITING

Outcomes

Primary Outcomes

Change in HbA1c

To assess change from baseline in HbA1c

Time frame: at 12 weeks

Secondary Outcomes

Change in HbA1c

To assess change from baseline in HbA1c

Time frame: at 24 weeks

The percentage of patients with HbA1c <7.0% and <6.5%

To assess the percentage of patients with HbA1c \<7.0% and \<6.5%

Time frame: at 12 and 24 weeks

Change in FPG

To assess change from baseline in fasting plasma glucose (FPG)

Time frame: at 12 and 24 weeks

Central Contacts

Jongchul Won, M.D., Ph.D.

CONTACT

+82-2-950-8860 dronjc@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.